A homologous booster shot involves the administration of the '''same''' vaccine as previously administered, while a heterologous booster shot involves the administration of a '''different''' vaccine.{{cn|date=December 2021}}
<blockquote>"'''Heterologous prime-boost immunization''' is administration of two '''different''' vectors or delivery systems expressing the same or overlapping antigenic inserts."<ref>{{cite web |title=WHO Technical Consultation: Heterologous Prime-Boost Immunization in Ebola vaccine development and testing, licensure and use; 21 November 2014 |url=https://www.who.int/immunization/research/meetings_workshops/Agenda_ebola_primeboost_nov14.pdf |website=[[World Health Organization]] |access-date=10 December 2021 |location=Geneva |date=2015-02-09}}</ref></blockquote>
<blockquote>"An effective vaccine usually requires more than one time immunization in the form of prime-boost. Traditionally the same vaccines are given multiple times as homologous boosts. New findings suggested that prime-boost can be done with '''different''' types of vaccines containing the same antigens. In many cases such heterologous prime-boost can be more immunogenic than homologous prime-boost."<ref name="Heterologous-PBV-2009">{{cite journal |last1=Lu |first1=S |title=Heterologous prime-boost vaccination. |journal=Current Opinion in Immunology |date=June 2009 |volume=21 |issue=3 |pages=346–51 |doi=10.1016/j.coi.2009.05.016 |pmid=19500964|pmc=3743086 }}</ref></blockquote>

==References==
{{Reflist}}

== Further reading ==
* {{cite web |title=Interim statement on booster doses for COVID-19 vaccination |url=https://www.who.int/news/item/04-10-2021-interim-statement-on-booster-doses-for-covid-19-vaccination |website=[[World Health Organization]] <!-- |access-date=11 December 2021 --> |language=en}}
* {{cite journal |last1=Liu |first1=Xinxue |last2=Shaw |first2=Robert H. |last3=Stuart |first3=Arabella S. V. |last4=Greenland |first4=Melanie |last5=Aley |first5=Parvinder K. |last6=Andrews |first6=Nick J. |last7=Cameron |first7=J. Claire |last8=Charlton |first8=Sue |last9=Clutterbuck |first9=Elizabeth A. |last10=Collins |first10=Andrea M. |last11=Dinesh |first11=Tanya |last12=England |first12=Anna |last13=Faust |first13=Saul N. |last14=Ferreira |first14=Daniela M. |last15=Finn |first15=Adam |last16=Green |first16=Christopher A. |last17=Hallis |first17=Bassam |last18=Heath |first18=Paul T. |last19=Hill |first19=Helen |last20=Lambe |first20=Teresa |last21=Lazarus |first21=Rajeka |last22=Libri |first22=Vincenzo |last23=Long |first23=Fei |last24=Mujadidi |first24=Yama F. |last25=Plested |first25=Emma L. |last26=Provstgaard-Morys |first26=Samuel |last27=Ramasamy |first27=Maheshi N. |last28=Ramsay |first28=Mary |last29=Read |first29=Robert C. |last30=Robinson |first30=Hannah |last31=Singh |first31=Nisha |last32=Turner |first32=David P. J. |last33=Turner |first33=Paul J. |last34=Walker |first34=Laura L. |last35=White |first35=Rachel |last36=Nguyen-Van-Tam |first36=Jonathan S. |last37=Snape |first37=Matthew D. |last38=Munro |first38=Alasdair P. S. |last39=Bartholomew |first39=Jazz |last40=Presland |first40=Laura |last41=Horswill |first41=Sarah |last42=Warren |first42=Sarah |last43=Varkonyi-Clifford |first43=Sophie |last44=Saich |first44=Stephen |last45=Adams |first45=Kirsty |last46=Ricamara |first46=Marivic |last47=Turner |first47=Nicola |last48=Ting |first48=Nicole Y. Yee |last49=Whittley |first49=Sarah |last50=Rampling |first50=Tommy |last51=Desai |first51=Amisha |last52=Brown |first52=Claire H. |last53=Qureshi |first53=Ehsaan |last54=Gokani |first54=Karishma |last55=Naker |first55=Kush |last56=Wright |first56=Johanna K. Kellett |last57=Williams |first57=Rachel L. |last58=Riaz |first58=Tawassal |last59=Penciu |first59=Florentina D. |last60=Maso |first60=Claudio Di |last61=Howe |first61=Elizabeth G. |last62=Vichos |first62=Iason |last63=Farooq |first63=Mujtaba Ghulam |last64=Noristani |first64=Rabiullah |last65=Yao |first65=Xin L. |last66=Oldfield |first66=Neil J. |last67=Hammersley |first67=Daniel |last68=Belton |first68=Sue |last69=Royal |first69=Simon |last70=Ramos |first70=Alberto San Francisco |last71=Hultin |first71=Cecilia |last72=Galiza |first72=Eva P. |last73=Shiham |first73=Farah |last74=Solórzano |first74=Carla |last75=Sainsbury |first75=Hannah |last76=Davies |first76=Kelly |last77=Ambrose |first77=Pauline |last78=Hitchins |first78=Lisa |last79=Baker |first79=Natalie |last80=Leung |first80=Stephanie |last81=Fothergill |first81=Ross |last82=Godwin |first82=Kerry |last83=Buttigieg |first83=Karen |last84=Shaik |first84=Imam |last85=Brown |first85=Phill |last86=Knight |first86=Chanice |last87=Lall |first87=Paminder |last88=Allen |first88=Lauren |title=Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial |journal=The Lancet |date=4 September 2021 |volume=398 |issue=10303 |pages=856–869 |doi=10.1016/S0140-6736(21)01694-9 |pmid=34370971 |pmc=8346248 |language=English |issn=0140-6736}}
*{{cite web |last1=Mukherjee |first1=Debabrata |title=Heterologous vs. Homologous Prime-Boost Schedules for COVID-19 Vaccines |url=https://www.acc.org/latest-in-cardiology/journal-scans/2021/09/10/15/03/safety-and-immunogenicity |website=[[American College of Cardiology]] <!-- |access-date=11 December 2021 |date=2021-09-10 --> |quote=The authors concluded that the SARS-CoV-2 anti-spike IgG concentrations of both heterologous schedules were higher than that of a licensed vaccine schedule (ChAd/ChAd) with proven efficacy against coronavirus disease 2019 (COVID-19) disease and hospitalization}}

{{Vaccines}}

[[Category:Vaccination]]

{{vaccine-stub}}